Status:

COMPLETED

A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease

Lead Sponsor:

Genzyme, a Sanofi Company

Conditions:

Fabry Disease

Eligibility:

All Genders

16+ years

Phase:

PHASE3

Brief Summary

People with Fabry disease have an alteration in their genetic material (DNA) which causes a deficiency of the a-galactosidase A enzyme. Fabrazyme is a drug that helps to breakdown and remove certain t...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Patients must have successfully completed the previous double-blind study (AGAL-1-002-98)
  • Patients must provide written informed consent prior to study participation
  • Female patients must have a negative pregnancy test prior to each dosing and use a medically accepted method of contraception throughout the study
  • Exclusion criteria:
  • Patient has undergone kidney transplant or is currently on dialysis
  • Patient is pregnant or lactating
  • Patient is unwilling to comply with the requirements of the protocol
  • Patient has a clinically significant organic disease (with the exception of symptoms related to Fabry disease), including clinically significant cardiovascular, hepatic, pulmonary, neurologic, or renal disease, or other medical condition, serious intercurrent illness, or extenuating circumstances that, in the opinion of the investigator, would preclude participation in the study

Exclusion

    Key Trial Info

    Start Date :

    October 1 1999

    Trial Type :

    INTERVENTIONAL

    End Date :

    December 1 2004

    Estimated Enrollment :

    58 Patients enrolled

    Trial Details

    Trial ID

    NCT00074971

    Start Date

    October 1 1999

    End Date

    December 1 2004

    Last Update

    December 4 2013

    Active Locations (20)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 5 (20 locations)

    1

    Cedars-Sinai Medical Center

    Los Angeles, California, United States, 90048

    2

    University of California San Fransisco

    San Francisco, California, United States, 94143

    3

    Northwest Oncology & Hematology Associates

    Coral Springs, Florida, United States, 33065

    4

    Children's Memorial Hospital

    Chicago, Illinois, United States, 60614

    A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease | DecenTrialz